Astellas has clearly been impressed with a partnership signed last August with Poseida Therapeutics on the development of cell therapies for solid tumours, as it has just
Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.
Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases.
California biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last week, seeking $115 million in funding for projects including a CAR